PharmaCyte Biotech's Dr. Mark Rabe Discusses the Significance of Schedule 1 License to Company's Future in Cannabis Research
18. Juni 2015 09:00 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - June 18, 2015) - PharmaCyte Biotech (OTCQB: PMCB) announced this week that the Company is able to advance its Cannabis research now that its research partner, The...
Nuvilex, Inc. Engaged in "Cutting Edge" Cannabis Preclinical Studies Using Model Compounds With Cell-in-a-Box
29. Oktober 2014 08:45 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - October 29, 2014) - Nuvilex, Inc. (OTCQB: NVLX) isn't letting the upcoming mid-term elections or the views in Washington, D.C., on medical marijuana slow down its...